Progressive multifocal leukoencephalopathy (PML), caused by JC virus (JCV), has remained one of the deadliest opportunistic infections in HIV-infected patients despite combined antiretroviral therapy, with only a 50% 1-year survival rate. Progressive multifocal leukoencephalopathy has also been diagnosed in patients with autoimmune diseases treated with immunomodulators such as natalizumab.
Progressive multifocal leukoencephalopathy (PML), caused by JC virus (JCV), has remained one of the deadliest opportunistic infections in HIV-infected patients despite combined antiretroviral therapy, with only a 50% 1-year survival rate. Progressive multifocal leukoencephalopathy has also been diagnosed in patients with autoimmune diseases treated with immunomodulators such as natalizumab. 1 A consistent feature of PML is the predominant location of lesions in the subcortical white matter on magnetic resonance imaging, with corresponding demyelinating areas at the gray-white junction (GWJ) on histology. Interestingly, 64% of brain metastases are also found at the GWJ. 2 This is likely owing to hemodynamic factors, where emboli of cancerous cells bind to endothelial receptors and remain in areas of sudden reduction of vascular caliber. Ultrastructural studies of the cortical microvasculature showed abrupt narrowing of perforating endarterioles coming from the brain surface into the cortical gray matter, with a dense bed of deep cortical capillaries at the GWJ. 3 JC virions may circulate either cell free or in association with B lymphocytes. 4 The virions can attach to the surface of a number of cell types and have the capability to aggregate type O erythrocytes, which is the basis of the hemagglutination inhibition assay, for detection of JCV antibody in patients' serum. The presence of JCV on the surface of B lymphocytes in individuals with type O blood may promote the aggregation of lymphocytes and erythrocytes, causing cell clumping that becomes impacted in narrow cortical capillaries with low blood flow at the GWJ. We sought to determine whether type O blood was a risk factor for PML.
Methods | We characterized ABO blood group antigen on blood samples of 76 patients with PML (62 were white and 14 were African American) followed up in our neurology clinic. Owing to their low number and different distribution of ABO blood group, African American individuals were excluded from statistical analyses. Of the 62 white patients with PML, 36 (58%) were HIV positive, 14 (23%) had underlying hematologic or oncologic diseases, and 12 (19%) included patients with autoimmune diseases, transplant recipients, idiopathic lymphocytopenia, or other forms of minimal immunosuppression. One patient had natalizumab-treated multiple sclerosis (MS). 
